- Conditions
- Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)
- Interventions
- Miricorilant, Fluvoxamine
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Interventions
- Miricorilant (Cohort A), Placebo (Cohort A), Miricorilant (Cohort B), Placebo (Cohort B)
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 48
- States / cities
- Chandler, Arizona • Tucson, Arizona • Huntington Park, California + 41 more
- Conditions
- Antipsychotic-induced Weight Gain (AIWG)
- Interventions
- Miricorilant, Placebo
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 27
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 23 more
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
- Interventions
- Miricorilant
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- Miricorilant 150 mg, Miricorilant 100 mg, Miricorilant 50 mg, Miricorilant 10 mg
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Chandler, Arizona • Tucson, Arizona • Panorama City, California + 6 more
- Conditions
- Healthy
- Interventions
- Miricorilant Treatment A, Miricorilant Treatment B, Miricorilant Treatment C, Miricorilant Treatment D
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida